DAFTAR PUSTAKA

1. Indonesia PDSK. Pedoman Tatalaksana Sindrom Koroner Akut 2018. *J Kardiol Indones www Ina org Diakses*. 2018;1.
2. Mehran R, Nikolsky E. Contrast-induced nephropathy: Definition, epidemiology, and patients at risk. *Kidney Int*. 2006;69:S11-S15.
3. Grossman W. *Grossman's Cardiac Catheterization, Angiography, and Intervention*. Lippincott Williams & Wilkins; 2006.
4. Doll JA, Hira RS, Kearney KE, et al. Management of percutaneous coronary intervention complications: algorithms from the 2018 and 2019 Seattle Percutaneous Coronary Intervention Complications Conference. *Circ Cardiovasc Interv*. 2020;13(6).
5. Go AS, Tan TC, Parikh R V, et al. Timing of AKI after urgent percutaneous coronary intervention and clinical outcomes: a high-dimensional propensity score analysis. *BMC Nephrol*. 2021;22:1-10.
6. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. *Nephron Clin Pract*. 2012;120(4):c179-c184.
7. Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. *Ann Transl Med*. 2016;4(13).
8. Ahmad M, Mehta P, Reddivari AKR, Mungee S. *Percutaneous Coronary Intervention*. StatPearls Publishing, Treasure Island (FL); 2023.
9. Tsai TT, Patel UD, Chang TI, et al. Contemporary Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions: Insights From the NCDR Cath-PCI Registry. *JACC Cardiovasc Interv*. 2014;7(1):1-9. doi:https://doi.org/10.1016/j.jcin.2013.06.016
10. Hiremath S, Akbari A, Wells GA, Chow BJW. Are iso-osmolar, as compared to low-osmolar, contrast media cost-effective in patients undergoing cardiac catheterization? An economic analysis. *Int Urol Nephrol*. 2018;50:1477-1482.
11. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. *J Am Soc Nephrol*. 2000;11(1):177-182.
12. Elserafy AS, Okasha N, Hegazy T. Prevention of contrast induced nephropathy by ischemic preconditioning in patients undergoing percutaneous coronary angiography. *Egypt Hear J*. 2018;70(2):107-111.
13. AO, Alshelleh SA, Daoud AK, Smadi MM, Alzoubi KH. Inflammatory n contrast-induced nephropathy: a prospective single-center study. *Int J Renovasc Dis*. Published online 2018:211-215.

14. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). *Eur Hear J Acute Cardiovasc Care*. 2024;13(1):55-161.
15. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2021;42(14):1289-1367.
16. Hung YM, Lin SL, Hung SY, Huang WC, Wang PYP. Preventing radiocontrast-induced nephropathy in chronic kidney disease patients undergoing coronary angiography. *World J Cardiol*. 2012;4(5):157.
17. Cioni G, Abouzaki NA, Jovin IS. Acute coronary syndrome: thrombotic lesions in patients with unstable angina. *Acad Press Cambridge, MA, USA*. Published online 2018:147-161.
18. Pasupathy S, Tavella R, McRae S, Beltrame JF. Myocardial infarction with non-obstructive coronary arteries–diagnosis and management. *Eur Cardiol Rev*. 2015;10(2):79.
19. Almeida AG. MINOCA and INOCA: Role in heart failure. *Curr Heart Fail Rep*. 2023;20(3):139-150.
20. Modi K, Padala SA, Gupta M. Contrast-induced nephropathy. Published online 2017.
21. Goldfarb S, McCullough PA, McDermott J, Gay SB. Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. In: *Mayo Clinic Proceedings*. Vol 84. Elsevier; 2009:170-179.
22. Mohebi R, Karimi Galougahi K, Garcia JJ, et al. Long-term clinical impact of contrast-associated acute kidney injury following PCI: an ADAPT-DES substudy. *Cardiovasc Interv*. 2022;15(7):753-766.
23. Heyman SN, Rosenberger C, Rosen S, Khamaisi M. Why is diabetes mellitus a risk factor for contrast-induced nephropathy? *Biomed Res Int*. 2013;2013.
24. Toprak O, Cirit M, Yesil M, et al. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease. *Nephrol Dial Transplant*. 2007;22(3):819-826.

G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after eous coronary interventions in relation to chronic kidney disease and

hemodynamic variables. *Am J Cardiol*. 2005;95(1):13-19.
26. Andra CA, Khairul A, Arina CA, Mukhtar Z, Kaoy IN. Contrast induced nephropathy in hypertensive patients after elective percutaneous coronary intervention. In: *IOP Conference Series: Earth and Environmental Science*. Vol 130. IOP Publishing; 2018:12006.
27. Lun Z, Mai Z, Liu L, et al. Hypertension as a Risk Factor for Contrast-Associated Acute Kidney Injury: A Meta-Analysis including 2,830,338 Patients. *Kidney Blood Press Res*. 2021;46(6):670-692.
28. Kroneberger C, Enzweiler CN, Schmidt-Lucke A, Rückert RI, Teichgräber U, Franiel T. Contrast-induced nephropathy in patients with chronic kidney disease and peripheral arterial disease. *Acta Radiol open*. 2015;4(6):2058460115583034.
29. Mehran R, Nikolsky E. Contrast-induced nephropathy: Definition, epidemiology, and patients at risk. *Kidney Int*. 2006;69(SUPPL. 100):S11-S15.
30. Hall KA, Wong RW, Hunter GC, et al. Contrast-induced nephrotoxicity: the effects of vasodilator therapy. *J Surg Res*. 1992;53(4):317-320.
31. Brown JR, Pearlman DM, Marshall EJ, et al. Meta-analysis of individual patient data of sodium bicarbonate and sodium chloride for all-cause mortality after coronary angiography. *Am J Cardiol*. 2016;118(10):1473-1479.
32. Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. *N Engl J Med*. 2017;378(7):603-614. https://doi.org/10.1056/NEJMoa1710933
33. Kong DG, Hou YF, Ma LL, Yao DK, Wang LX. Comparison of oral and intravenous hydration strategies for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography or angioplasty: a randomized clinical trial. *Acta Cardiol*. 2012;67(5):565-569.
34. Li W hua, Li D ye, Han F, Xu T da, Zhang Y bing, Zhu H. Impact of anemia on contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary interventions. *Int Urol Nephrol*. 2013;45:1065-1070.
35. Wang W, Qu W, Sun D, Liu X. Meta-analysis of effect of renin-angiotensin-aldosterone system blockers on contrast-induced nephropathy. *J Renin Angiotensin Aldosterone Syst*. 2020;21(2):1470320320919587.
36. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. *AJR Am J Roentgenol*. 2004;183(6):1673-1689.

l M, Hałubiec P, Łazarczyk A, et al. Low ejection fraction predisposes to induced nephropathy after the second step of staged coronary

revascularization for acute myocardial infarction: a retrospective observational study. *J Clin Med*. 2020;9(6):1812.

38. He H, Chen XR, Chen YQ, Niu TS, Liao YM. Prevalence and predictors of contrast-induced nephropathy (CIN) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI): a meta-analysis. *J Interv Cardiol*. 2019;2019.
39. Silver SA, Shah PM, Chertow GM, Harel S, Wald R, Harel Z. Risk prediction models for contrast induced nephropathy: systematic review. *Bmj*. 2015;351.
40. Mehran R, Dangas GD, Weisbord SD. Contrast-associated acute kidney injury. *N Engl J Med*. 2019;380(22):2146-2155.
41. Hossain MA, Costanzo E, Cosentino J, et al. Contrast-induced nephropathy: Pathophysiology, risk factors, and prevention. *Saudi J Kidney Dis Transplant*. 2018;29(1):1-9.
42. Andreucci M, Faga T, Pisani A, Sabbatini M, Russo D, Michael A. Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors. *Sci World J*. 2014;2014.
43. Kusirisin P, Chattipakorn SC, Chattipakorn N. Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches. *J Transl Med*. 2020;18(1):1-35.
44. Simsek A, Tugcu V, Tasci AI. New biomarkers for the quick detection of acute kidney injury. *Int Sch Res Not*. 2013;2013.
45. Andreucci M, Faga T, Riccio E, Sabbatini M, Pisani A, Michael A. The potential use of biomarkers in predicting contrast-induced acute kidney injury. *Int J Nephrol Renovasc Dis*. Published online 2016:205-221.
46. Firouzi A, Alemzadeh-Ansari MJ, Mohammadhadi N, et al. Association between the risks of contrast-induced nephropathy after diagnostic or interventional coronary management and the transradial and transfemoral access approaches. *J Cardiovasc Thorac Res*. 2020;12(1):51-55. doi:10.34172/jcvtr.2020.08
47. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. *Circulation*. 2002;105(19):2259-2264.
48. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Wiviott SD. Short-term outcomes of acute myocardial infarction in patients with acute kidney injury: a report national cardiovascular data registry. *Circulation*. 2012;125(3):497-504.
, van der Giet M, Schwarzfeld C. Acetylcysteine and nephrotoxic effects of

radiographic contrast agents—a new use for an old drug. *N EnglJ Med*. 2000;343(3):180-184.
50. Gupta RK, Bang TJ. Prevention of contrast-induced nephropathy (CIN) in interventional radiology practice. In: *Seminars in Interventional Radiology*. Vol 27. © Thieme Medical Publishers; 2010:348-359.
51. Tavakol M, Ashraf S, Brener SJ. Risks and complications of coronary angiography: a comprehensive review. *Glob J Health Sci*. 2012;4(1):65.
52. Soelistijo SA, Lindarto D, Decroli E, et al. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia 2021. *Perkumpulan Endokrinol Indones*. 2021;4:1-117.
53. Council ES, Redon J, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Eur Heart J*. 2013;34(28):2159-2219.
54. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2021;42(36):3599-3726.
55. Vahdatpour C, Collins D, Goldberg S. Cardiogenic shock. *J Am Heart Assoc*. 2019;8(8).
56. Levin A, Stevens PE, Bilous RW, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl*. 2013;3(1):1-150.
57. Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. *BMC Nephrol*. 2017;18(1):1-29.
58. Bhandari P, Shah Z, Patel K, Patel R. Contrast-induced acute kidney injury following coronary angiography in patients with end-stage liver disease. *J community Hosp Intern Med Perspect*. 2019;9(5):403-409.
59. Abe M, Morimoto T, Akao M, et al. Relation of contrast-induced nephropathy to long-term mortality after percutaneous coronary intervention. *Am J Cardiol*. 2014;114(3):362-368.
60. Shams E, Mayrovitz HN. Contrast-induced nephropathy: a review of mechanisms and risks. *Cureus*. 2021;13(5).
ne E, Phayphet M, Thibaudin D, Barral FG, Veyret C. Contrast medium-acute renal failure and cholesterol embolism after radiological procedures:

incidence, risk factors, and compliance with recommendations. *Eur J Intern Med*. 2003;14(7):426-431.

62. Piskinpasa S, Altun B, Akoglu H, et al. An uninvestigated risk factor for contrast-induced nephropathy in chronic kidney disease: proteinuria. *Ren Fail*. 2013;35(1):62-65.
63. Ugur MC, Ekinci F, Soyaltın UE, Akar H. Contrast Induced Nephropathy in Patients with Acute Coronary Syndrome. *Editor Board*. Published online 2015:10.
64. Conen D, Buerkle G, Perruchoud AP, Buettner HJ, Mueller C. Hypertension is an independent risk factor for contrast nephropathy after percutaneous coronary intervention. *Int J Cardiol*. 2006;110(2):237-241.
65. Pavasini R, Tebaldi M, Bugani G, et al. Contrast associated acute kidney injury and mortality in older adults with acute coronary syndrome: a pooled analysis of the FRASER and HULK studies. *J Clin Med*. 2021;10(10):2151.
66. Dodson JA, Hajduk A, Curtis J, et al. Acute kidney injury among older patients undergoing coronary angiography for acute myocardial infarction: the SILVER-AMI study. *Am J Med*. 2019;132(12):e817-e826.
67. Anderson S, Eldadah B, Halter JB, et al. Acute kidney injury in older adults. *J Am Soc Nephrol*. 2011;22(1):28-38.
68. Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol*. 2004;44(9):1780-1785.
69. Palli E, Makris D, Papanikolaou J, Garoufalis G, Zakynthinos E. Contrast-induced nephropathy in aged critically ill patients. *Oxid Med Cell Longev*. 2014;2014. doi:10.1155/2014/756469
70. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol*. 2004;44(7):1393-1399.
71. Fu N, Li X, Yang S, et al. Risk score for the prediction of contrast-induced nephropathy in elderly patients undergoing percutaneous coronary intervention. *Angiology*. 2013;64(3):188-194.
72. Sreenivasan J, Zhuo M, Khan MS, et al. Anemia (Hemoglobin ≤ 13 g/dL) as a Risk Factor for Contrast-Induced Acute Kidney Injury Following Coronary Angiography. *Am J Cardiol*. 2018;122(6):961-965. doi:10.1016/j.amjcard.2018.06.012